Vicebio has agreed to be acquired by Sanofi for a total of $1.6 billion, including an upfront payment of $1.15 billion as well as development and regulatory milestones payments of $450 million.  Vicebio was created by Medicxi to develop vaccines for respiratory viruses utilising its proprietary Molecular Clamp technology, discovered at The University of Queensland.   […]